You need a license to cut-and-paste this copyrighted news content. Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe Already a paid subscriber? Sign in to Endpoints News to remove this message. Spark Therapeutics $ONCE  has scored an historic FDA approval of Luxturna, the world’s […]

Leer Más "LA FDA DA EL OK PARA LA TERAPIA GENÉTICA DE LA MUTACIÓN RPE65"